Loading clinical trials...
Loading clinical trials...
Randomized Phase II Study of Amrubicin as Single Agent or in Combination With Cisplatin Versus Etoposide-cisplatin as First-line Treatment in Patients With Extensive Stage SCLC (ES)
Conditions
Interventions
Amrubicin
Cisplatin
+1 more
Locations
25
Belgium
Algemeen Ziekenhuis Middelheim
Antwerp, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Universiteit Gent
Ghent, Belgium
U.Z. Gasthuisberg
Leuven, Belgium
Domaine Universitaire du Sart-Tilman
Liège, Belgium
Centre Hospitalier Regional de la Citadelle
Liège, Belgium
Start Date
November 1, 2006
Primary Completion Date
April 1, 2010
Completion Date
December 1, 2010
Last Updated
November 19, 2019
NCT06066138
NCT06305754
NCT07190248
NCT07485114
NCT05692635
NCT07100080
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions